One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting (COVENTRY)

April 26, 2023 updated by: Groupe Hospitalier Paris Saint Joseph

Quality of Life and Functional Prognosis at One Year of Patients With COVID-19 Admitted in Post-ICU Setting

The COVID-19 disease has been subject to numerous publications since its emergence. Almost 20% of people suffering from COVID-19 develop severe to critical symptoms and require hospitalization, often in Intensive Care Unit (ICU). Respiratory failure is the main reason for admission in ICU of these patients. Therapeutic strategies implemented for the management of critically-ill patients may often lead to short-term muscular and functional alterations resulting in ICU-Acquired Weakness (ICUAW). These lead to long-term disabilities expressing trough dependence and quality of life impairment of survivors.

The purpose of this study is to assess the quality of life, dependence and survival at one year in patients who survived from COVID-19 in ICU and are admitted in post-ICU setting for difficult weaning purpose.

Ancillary studies aim to assess the course of muscle function (atrophy, structural modifications), lung function (loss of aeration) and safety of early mobilization.

Study Overview

Detailed Description

SARS-Cov-2, a virus causing a new infectious disease called COVID-19, has been subject to numerous publications since its emergence. Almost 20% of people infected with SARS-Cov-2 develop severe to critical symptoms and required hospitalization, often in Intensive Care Unit (ICU).

Respiratory failure is the main reason for admission in ICU of patients with COVID-19, which develop an Acute Respiratory Distress Syndrome (ARDS). Respiratory failure may be associated to liver, renal, coagulation and hemodynamic failure.

Therapeutic strategies implemented for the management of critically-ill patients with COVID-19 may often lead to short-term muscular and functional alterations resulting in ICU-Acquired Weakness (ICUAW), as studied in other ICU population.

The muscular and functional impairments of patients are associated to a longer duration of mechanical ventilation and hospital length of stay and increased mortality. Long-term impacts are also reported like dependence and quality of life impairment of survivors.

The COVID-19 pandemic currently leads to an increasing number of ICU admission in France with a high risk of settings saturation. Specialized settings for post-ICU rehabilitation are preparing to early receive difficult-to-wean patients with ICUAW after admission in ICU for severe or critical form of COVID-19.

To our best knowledge, no data is obviously available regarding at the future of these patients in terms of quality of life, dependence or survival. Moreover, no short-term data are available concerning the course of lung damages and muscle function after ICU stay. The safety of early mobilization usually delivered in patients admitted to post-ICU settings has never been assessed in patients with COVID-19.

The purpose of this study is to assess the quality of life, dependence and survival at one year in patients who survived from COVID-19 in ICU and are admitted in post-ICU setting for difficult weaning purpose.

Ancillary studies aim to assess course of muscle function (atrophy, structure modification), lung function (loss of aeration) and safety of early mobilization.

Study Type

Observational

Enrollment (Actual)

65

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hauts-de-France
      • Beuvry, Hauts-de-France, France, 62660
        • Centre Hospitalier de Béthune
    • Ile De France
      • Paris, Ile De France, France, 75013
        • APHP - Hôpital Universitaire Pitié-Salpétrière
    • Ile-de-France
      • Férolles-Attilly, Ile-de-France, France, 77150
        • Hôpital Forcilles

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who were initially hospitalized in ICU for COVID-19 and then admitted in a post-ICU setting for difficult weaning purpose.

Description

Inclusion Criteria:

  • Patient initially hospitalized in ICU for COVID-19;
  • Admitted in post-ICU setting (difficult-to-wean unit);
  • Age > 18 years old;
  • Membership of a social insurance sheme;
  • Medical prescription of early mobilization;
  • Patient or relative provides consent.

Exclusion Criteria:

  • Known pregnancy ;
  • Person subject to judicial health protection;
  • Patient under legal guardianship or curatorship;
  • Contraidication for early mobilization;
  • Decision to withhold lifesustaining treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Principal cohort

Quality of life, autonomy and survival will be assessed at one year on 50 patients.

Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization.

Lung cohort
Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.

Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.

Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded.

Muscle cohort
Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.

Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.

Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean in quality of life score at one year on the Short Form Health Survey (SF-36)
Time Frame: 1 year
Quality of life will be assessed using Short Form Health Survey (SF-36) through a phone call at one year. SF-36 score range from 0 to 100, 100 indicating a better quality of life.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean in autonomy score on the Activities Daily Living (ADL) scale
Time Frame: At enrollement and 1 year

Autonomy will be assessed using Activities Daily Living (ADL) scale through a phone call at one year and six months.

ADL scale range from 0 to 6, 6 indicating a better autonomy in activities daily living.

At enrollement and 1 year
Survival rate
Time Frame: 1 year
Survival will be assessed using the death registry query and phone call for vital status recording at six months and one year. Survival rate will be expressed as a survival function using Kaplan Meier method.
1 year
Change from baseline in lung ultrasound aeration score
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Lung aeration will be assessed using the Lung Ultrasound Score (LUS). Patient is in semi-recumbent position (30°). Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.

Lung Ultrasound Score will be recorded using a convex probe with a transverse view.

For each thorax area a subscore is calculated: 0 = normal profil; 1 = multiple and well-defined B-lines; 2 = confluent B-lines; 3 = lung consolidation.

Sum of this subscores allows calculation of the total score out of 60. Presence of pleural thickening and subpleural consolidations will be also recorded.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Change from baseline in diaphragm ultrasound thickness and excursion
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Diaphragm Ultrasound will be used to assess diaphragm thickness and excursion. Patient is in semi-recumbent position (30°). Diaphragm thickness will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness. M-Mode will be used to measure diaphragm thickness at inspiratory time (maximal inspiration) and expiratory time (maximal expiration).

Diaphragm excursion will be measured using a subcostal anterior view with convex probe. Excursion measurement is performed in M-mode as the distance between end-inspiration and end-expiration.

Three measures of both DTF and excursion will performed and the better will be kept.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Mean change from baseline in ultrasound muscle thickness
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Muscle ultrasound measurements will be performed using a linear probe with a transverse view.

Thickness (cm) of vastus intermedius, rectus femori and tibialis anterior will be measured.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Mean change from baseline in ultrasound muscle cross-sectionnal area
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Muscle ultrasound measurements will be performed using a linear probe with a transverse view.

Cross-sectionnal area (CSA) (cm^2) of rectus femori and tibialis anterior will be measured.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Mean change from baseline in ultrasound muscle echogeneicity
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Muscle ultrasound measurements will be performed using a linear probe with a transverse view.

Echogeneicity (0 to 255) of rectus femori and tibialis anterior will be measured using Image J software. Penation angle of rectus femori will be assessed.

is used to measure muscle thicknesses, CSA and echogeneicity. Longitudinal view is used to measure angle of pennation.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Mean change from baseline in ultrasound muscle pennation
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU

Muscle ultrasound measurements will be performed using a linear probe with a longitudinal view.

Penation angle (°) of rectus femori will be assessed.

Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Mean change from baseline in Medical Research Council (MRC) sum score
Time Frame: Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
MRC sum score evaluates strength in three muscle groups of all four limbs. A score between 0 and 5 is assigned to each of them, which renders a maximum total score of 60.
Day of enrollement, day 14, day 21, day 28 and day 35 from initial admission in ICU
Prevalence of adverse outcomes during early mobilization
Time Frame: From date of enrollement up to 30 days (date of estimated post-ICU discharge)
Number of adverse outcomes during early mobilization of patients will recorded at each mobilization session. Prevalence of adverse outcomes is expressed as the number of adverse outcomes divided by the number of early mobilization sessions.
From date of enrollement up to 30 days (date of estimated post-ICU discharge)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Aymeric LE NEINDRE, PT, PhD, Hôpital Forcilles

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 16, 2020

Primary Completion (Actual)

July 13, 2021

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

April 26, 2020

First Submitted That Met QC Criteria

May 1, 2020

First Posted (Actual)

May 4, 2020

Study Record Updates

Last Update Posted (Actual)

April 27, 2023

Last Update Submitted That Met QC Criteria

April 26, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data that support the findings of this study will be openly available in "figshare".

IPD Sharing Time Frame

Data will be available at publication of the results.

IPD Sharing Access Criteria

Data openly available in a public repository that issues datasets with DOIs

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Lung ultrasound

3
Subscribe